New COVID-19 & Long COVID Protocols Reviewed by Medical Experts

Posted by Julia M.
4
Healthcare & Medical
Aug 28, 2025
204 Views

Summary (lead):
A new comprehensive guide has been published on My Canadian HealthCare Mall, covering the updated 2025 treatment protocols for Stromectol (ivermectin) in COVID-19, Long COVID, flu, and RSV management. Written by Douglas C. Goldberg, MD, and reviewed by leading oncologist Dr. Philip Schein, the article provides patients and healthcare readers with practical insights on safe use, dosage, international guidelines, and online purchasing options.

Body (main text):
August 25, 2025 – Bryn Mawr, PA
Stromectol (ivermectin) remains one of the most discussed and researched medications in the context of COVID-19 and post-COVID recovery. While initially approved as an antiparasitic drug, recent independent protocols highlight its role as an antiviral and immunomodulatory therapy in infectious diseases, including COVID-19, RSV, and influenza.

The new article –  Ivermectin – Updated COVID-19 Treatment Guide (2025) – is now available at:
? Read full article here

Key highlights from the publication:

  • Updated protocols (I-PREVENT & I-CARE): covering prophylaxis, early treatment, and Long COVID management strategies.

  • Dosage guidance: comparison between approved parasitic treatment and off-label COVID regimens.

  • Safety considerations: contraindications, side effects, and importance of medical supervision.

  • Buying options: comparison of local vs international online pharmacies, including generics and pricing models.

  • Patient relevance: more than 95% of current online Stromectol purchases are related to COVID-19 or post-COVID conditions.

Dr. Philip Schein, a renowned oncologist and hematology specialist from Bryn Mawr, Pennsylvania, has peer-reviewed the publication, ensuring the medical accuracy and credibility of presented data.

“Ivermectin’s role in infectious disease management deserves careful, evidence-based discussion. This guide provides balanced insights into its potential benefits and limitations in COVID-19 treatment,” said Dr. Schein.

About the Author

Douglas C. Goldberg, MD, is a medical researcher and health writer with expertise in clinical pharmacology and evidence-based medicine.

Source & Contact

? Full article: My Canadian HealthCare Mall
✉️ Contact: info@mycanadianhealthcaremall.com

1 people like it
avatar
Comments
avatar
Please sign in to add comment.
Advertise on APSense
This advertising space is available.
Post Your Ad Here
More Articles